5. Conclusions
CD is still considered a global health problem with significant epidemiological and socioeconomic implications. In recent years, technical advances in several areas have contributed to a better understanding of the biology and life cycle of this parasite, which will make it possible to design the ideal profile of both drugs and therapeutic options for treating CD. Here, we present T. cruziArequipa strain as an interesting tool for drug discovery against CD. For in vitro assays, several different strains should be used for the evaluation of the spectrum of action of potential compounds. However, for in vivo assays, and in order to fulfil the principles of the 3Rs (Replacement, Reduction and Refinement) in animal research, T. cruzi Arequipa can be the strain of choice. The tropism of this strain makes it ideal for the evaluation of potential compounds with the aim of selecting those with the best anti-Chagas profile.